ArticleUltrasound in medicine & biology2013
Acoustic characterization and pharmacokinetic analyses of new nanobubble ultrasound contrast agents.
Article in Ultrasound in medicine & biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 138 citations in OpenAlex.
- Preclinical evaluation of PSMA-targeted ultrasound contrast agents in an orthotopic model of prostate cancer in rabbits.Bioactive materials · 2027Article
- Review
- Volumetric Passive Acoustic Mapping and Cavitation Detection of Nanobubbles under Low-Frequency Insonation.ACS materials Au · 2025Article
- Cross Amplitude Modulation and Compound Amplitude Modulation for Nonlinear Contrast-Enhanced Ultrasound Imaging of Nanobubbles.IEEE open journal of ultrasonics, ferroelectrics, and frequency control · 2025Article
- Drug Release via Ultrasound-Activated Nanocarriers for Cancer Treatment: A Review.Pharmaceutics · 2024Review
- Quantification of extravasation and binding of PSMA-targeted nanobubbles by modelling the second-wave phenomenon.Molecular imaging and biology · 2024Article
- Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - Direct comparison of doxorubicin-loaded nanobubbles and microbubbles.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - Direct comparison of doxorubicin-loaded nanobubbles and microbubbles.bioRxiv : the preprint server for biology · 2023Article
- Nanobubble size distribution measurement by interactive force apparatus under an electric field.Scientific reports · 2023Article
- Ultrasound contrast agents from microbubbles to biogenic gas vesicles.Medical review (2021) · 2023Review
- Functional evaluation of constructed pseudo-endogenous microRNA-targeted myocardial ultrasound nanobubble.Frontiers in medicine · 2023Article
- Characterization of the interaction of nanobubble ultrasound contrast agents with human blood components.Bioactive materials · 2023Article
- Medical Imaging Technology and Imaging Agents.Advances in experimental medicine and biology · 2023Article
- The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer.International journal of nanomedicine · 2023Article
- Pharmacokinetic modeling of PSMA-targeted nanobubbles for quantification of extravasation and binding in mice models of prostate cancer.Medical physics · 2022Article
- The unique second wave phenomenon in contrast enhanced ultrasound imaging with nanobubbles.Scientific reports · 2022Article
- Iridium(III) Complex-Loaded Perfluoropropane Nanobubbles for Enhanced Sonodynamic Therapy.Bioconjugate chemistry · 2022Article
- Biomimetic nanobubbles for triple-negative breast cancer targeted ultrasound molecular imaging.Journal of nanobiotechnology · 2022Article
- Intracellular vesicle entrapment of nanobubble ultrasound contrast agents targeted to PSMA promotes prolonged enhancement and stabilityNanotheranostics · 2022Article
- Acoustics at the nanoscale (nanoacoustics): A comprehensive literature review.: Part II: Nanoacoustics for biomedical imaging and therapy.Sensors and actuators. A, Physical · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
In contrast to the clinically used microbubble ultrasound contrast agents, nanoscale bubbles (or nanobubbles) may potentially extravasate into tumors that exhibit more permeable vasculature, facilitating targeted molecular imaging and drug delivery. Our group recently presented a simple strategy using the non-ionic surfactant Pluronic as a size control excipient to produce nanobubbles with a mean diameter of 200 nm that exhibited stability and echogenicity on par with microbubbles. The objective of this study was to carry out an in-depth characterization of nanobubble properties as compared with Definity microbubbles, both in vitro and in vivo. Through use of a tissue-mimicking phantom, in vitro experiments measured the echogenicity of the contrast agent solutions and the contrast agent dissolution rate over time. Nanobubbles were found to be more echogenic than Definity microbubbles at three different harmonic frequencies (8, 6.2 and 3.5 MHz). Definity microbubbles also dissolved 1.67 times faster than nanobubbles. Pharmacokinetic studies were then performed in vivo in a subcutaneous human colorectal adenocarcinoma (LS174T) in mice. The peak enhancement and decay rates of contrast agents after bolus injection in the liver, kidney and tumor were analyzed. No significant differences were observed in peak enhancement between the nanobubble and Definity groups in the three tested regions (tumor, liver and kidney). However, the decay rates of nanobubbles in tumor and kidney were significantly slower than those of Definity in the first 200-s fast initial phase. There were no significant differences in the decay rates in the liver in the initial phase or in three regions of interest in the terminal phase. Our results suggest that the stability and acoustic properties of the new nanobubble contrast agents are superior to those of the clinically used Definity microbubbles. The slower washout of nanobubbles in tumors suggests potential entrapment of the bubbles within the tumor parenchyma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.